User:ChrisMisu/Drug pipeline

Article body
Some biotechnology companies, which are at or near the clinical stage and have attracted investors, are often bought by large pharmaceutical companies for high prices. However, these biotech companies may face failures, particularly in producing near-term products. This can lead to the shutdown of the acquired companies, resulting in the loss of accumulated knowledge and expertise.